Table 1 Baseline characteristics TCGA vs validation cohort.
From: Myo1e overexpression in lung adenocarcinoma is associated with increased risk of mortality
Patient characteristics | Validation cohort (N = 127) | TCGA (N = 1017) |
|---|---|---|
Age at diagnosis (years) (IQR) | 66 (59–70) | 67 (60–73) |
Gender | ||
 Male (%) | 97 (76%) | 609 (60%) |
 Female (%) | 30 (34%) | 408 (40%) |
Race | ||
 Caucasians (%) | 90 (71%) | 738 (73%) |
 African Americans (%) | 35 (8%) | 82 (8%) |
 Asians (%) | 2 (2%) | 17 (2%) |
 American Indian or Alaska native (%) | 0 (0%) | 1 (< 1%) |
 Non reported (%) | 0 (0%) | 179 (18%) |
Pack-year (IQR) | 40 (0–55) | 40 (29–60) |
Histology | ||
 Adenocarcinoma (LUAD) (%) | 66 (52%) | 515 (51%) |
 Squamous-cell (LUSC) (%) | 55 (48%) | 502 (49%) |
Stage | ||
 I (%) | 63 (50%) | 520 (52%) |
 II (%) | 31 (24%) | 284 (28%) |
 III (%) | 30 (24%) | 168 (17%) |
 IV (%) | 3 (2%) | 33 (3%) |
